InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
BEIJING--(BUSINESS WIRE)--InnoCare (HKEX: 09969; SSE:688428) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has…